| ［1］ |
Sun Y， Shen Y， Liu Q，et al. Global trends in melanoma burden：a comprehensive analysis from the Global Burden of Disease Study，1990-2021［J］. J Am Acad Dermatol， 2025， 92（1）：100-107. DOI： 10.1016/j.jaad.2024.09.035.
|
| ［2］ |
Vestergaard CD， Ellebaek E， Borch TH，et al. The challenge of treating anti-PD-1-resistant advanced melanoma［J］. Am J Clin Dermatol， 2025， 26（5）：777-794. DOI： 10.1007/s40257-025-00969-1.
|
| ［3］ |
Dagogo-Jack I， Shaw AT. Tumour heterogeneity and resistance to cancer therapies［J］. Nat Rev Clin Oncol， 2018， 15（2）：81-94. DOI： 10.1038/nrclinonc.2017.166.
|
| ［4］ |
Sade-Feldman M， Yizhak K， Bjorgaard SL，et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma［J］. Cell， 2018， 175（4）：998-1013e20. DOI： 10.1016/j.cell.2018.10.038.
|
| ［5］ |
Zheng DX， Bozym DJ， Tarantino G，et al. Overcoming resistance mechanisms to melanoma immunotherapy［J］. Am J Clin Dermatol， 2025， 26（1）：77-96. DOI： 10.1007/s40257-024-00907-7.
|
| ［6］ |
Dhatchinamoorthy K， Colbert JD， Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation［J］. Front Immunol， 2021， 12：636568. DOI： 10.3389/fimmu.2021.636568.
|
| ［7］ |
Galluzzi L， Vitale I， Aaronson SA，et al. Molecular mechanisms of cell death：recommendations of the Nomenclature Committee on Cell Death 2018［J］. Cell Death Differ， 2018， 25（3）：486-541. DOI： 10.1038/s41418-017-0012-4.
|
| ［8］ |
|
| ［9］ |
Pandian N， Kanneganti TD. PANoptosis：a unique innate immune inflammatory cell death modality［J］. J Immunol， 2022， 209（9）：1625-1633. DOI： 10.4049/jimmunol.2200508.
|
| ［10］ |
Lin JF， Wang TT， Huang RZ，et al. PANoptosis in cancer：bridging molecular mechanisms to therapeutic innovations［J］. Cell Mol Immunol， 2025， 22（9）：996-1011. DOI： 10.1038/s41423-025-01329-z.
|
| ［11］ |
Wang WQ， Zhou Z， Ge FX，et al. Role of PANoptosis in cancer：molecular mechanisms and therapeutic opportunities［J］. Apoptosis， 2025， 30（11-12）：2722-2744. DOI： 10.1007/s10495-025-02173-2.
|
| ［12］ |
Xie J， Zhang P， Xu X，et al. PANoptosis-related signature in melanoma：transcriptomic mapping and clinical prognostication［J］. Environ Toxicol， 2024， 39（5）：2545-2559. DOI： 10.1002/tox.24126.
|
| ［13］ |
Upmanyu K， Upadhyay S. Wiring and rewiring PANoptosis：molecular vulnerabilities for targeting inflammatory cell death in human disease［J］. Cytokine Growth Factor Rev， 2025， 86：1-16. DOI： 10.1016/j.cytogfr.2025.09.003.
|
| ［14］ |
Wang D， Fu Z， Gao L，et al. Increased IRF9-STAT2 signaling leads to adaptive resistance toward targeted therapy in melanoma by restraining GSDME-dependent pyroptosis［J］. J Invest Dermatol， 2022， 142（9）：2476-2487e9. DOI： 10.1016/j.jid.2022.01.024.
|
| ［15］ |
Shi C， Cao P， Wang Y，et al. PANoptosis：a cell death characterized by pyroptosis，apoptosis，and necroptosis［J］. J Inflamm Res， 2023， 16：1523-1532. DOI： 10.2147/JIR.S403819.
|
| ［16］ |
Sun X， Yang Y， Meng X，et al. PANoptosis：mechanisms，biology，and role in disease［J］. Immunol Rev， 2024， 321（1）：246-262. DOI： 10.1111/imr.13279.
|
| ［17］ |
Zhu P， Ke ZR， Chen JX，et al. Advances in mechanism and regulation of PANoptosis：prospects in disease treatment［J］. Front Immunol， 2023， 14：1120034. DOI： 10.3389/fimmu.2023.1120034.
|
| ［18］ |
Qi Z， Zhu L， Wang K，et al. PANoptosis：emerging mechanisms and disease implications［J］. Life Sci， 2023， 333：122158. DOI： 10.1016/j.lfs.2023.122158.
|
| ［19］ |
Huang Y， Wang L， Zhu Y，et al. Z-DNA-binding protein 1-mediated programmed cell death：mechanisms and therapeutic implications［J］. Chin Med J （Engl）， 2025， 138（19）：2421-2451. DOI： 10.1097/CM9.0000000000003737.
|
| ［20］ |
Karki R， Kanneganti TD. ADAR1 and ZBP1 in innate immunity，cell death，and disease［J］. Trends Immunol， 2023， 44（3）：201-216. DOI： 10.1016/j.it.2023.01.001.
|
| ［21］ |
Cheng H， Yu J， Wong CC. Adenosine-to-inosine RNA editing in cancer：molecular mechanisms and downstream targets［J］. Protein Cell， 2025， 16（6）：391-417. DOI： 10.1093/procel/pwae039.
|
| ［22］ |
Arroyo Villora S， Castellanos Silva P， Zenz T，et al. Biomarker RIPK3 is silenced by hypermethylation in melanoma and epigenetic editing reestablishes its tumor suppressor function［J］. Genes （Basel）， 2024， 15（2）：175. DOI： 10.3390/genes15020175.
|
| ［23］ |
Zhu H， Zhao M， Chang C，et al. The complex role of AIM2 in autoimmune diseases and cancers［J］. Immun Inflamm Dis， 2021， 9（3）：649-665. DOI： 10.1002/iid3.443.
|
| ［24］ |
Fukuda K， Okamura K， Riding RL，et al. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma［J］. J Exp Med， 2021， 218（9）：e20200962. DOI： 10.1084/jem.20200962.
|
| ［25］ |
van der Leun AM， Thommen DS， Schumacher TN. CD8 + T cell states in human cancer：insights from single-cell analysis［J］. Nat Rev Cancer， 2020， 20（4）：218-232. DOI： 10.1038/s41568-019-0235-4.
|
| ［26］ |
Furuta K， Onishi H， Ikada Y，et al. ATP and its metabolite adenosine cooperatively upregulate the antigen-presenting molecules on dendritic cells leading to IFN-gamma production by T cells［J］. J Biol Chem， 2023， 299（4）：104587. DOI： 10.1016/j.jbc.2023.104587.
|
| ［27］ |
Liu X， Song X， Li G，et al. HMGB1 regulates the activation of dendritic cells and CD4 + T cell responses through the modulation of autophagy in bleomycin-induced pulmonary fibrosis［J］. Immunobiology， 2025， 230（3）：152906. DOI： 10.1016/j.imbio.2025.152906.
|
| ［28］ |
Exconde PM， Hernandez-Chavez C， Bourne CM，et al. The tetrapeptide sequence of IL-18 and IL-1beta regulates their recruitment and activation by inflammatory caspases［J］. Cell Rep， 2023， 42（12）：113581. DOI： 10.1016/j.celrep.2023.113581.
|
| ［29］ |
Hughes SA， Lin M， Weir A，et al. Caspase-8-driven apoptotic and pyroptotic crosstalk causes cell death and IL-1beta release in X-linked inhibitor of apoptosis （XIAP） deficiency［J］. EMBO J， 2023， 42（5）：e110468. DOI： 10.15252/embj.2021110468.
|
| ［30］ |
Caronni N， La Terza F， Frosio L，et al. IL-1β + macrophages and the control of pathogenic inflammation in cancer［J］. Trends Immunol， 2025， 46（5）：403-415. DOI： 10.1016/j.it.2025.03.001.
|
| ［31］ |
Leone P， Malerba E， Susca N，et al. Endothelial cells in tumor microenvironment：insights and perspectives［J］. Front Immunol， 2024， 15：1367875. DOI： 10.3389/fimmu.2024.1367875.
|
| ［32］ |
Karki R， Sundaram B， Sharma BR，et al. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis［J］. Cell Rep， 2021， 37（3）：109858. DOI： 10.1016/j.celrep.2021.109858.
|
| ［33］ |
Kumar PR， Moore JA， Bowles KM，et al. Mitochondrial oxidative phosphorylation in cutaneous melanoma［J］. Br J Cancer， 2021， 124（1）：115-123. DOI： 10.1038/s41416-020-01159-y.
|
| ［34］ |
D'Aguanno S， Mallone F， Marenco M，et al. Hypoxia-dependent drivers of melanoma progression［J］. J Exp Clin Cancer Res， 2021， 40（1）：159. DOI： 10.1186/s13046-021-01926-6.
|
| ［35］ |
Liu X， Zhang Z， Ruan J，et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores［J］. Nature， 2016， 535（7610）：153-158. DOI： 10.1038/nature18629.
|
| ［36］ |
Dietl K， Renner K， Dettmer K，et al. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes［J］. J Immunol， 2010， 184（3）：1200-1209. DOI： 10.4049/jimmunol.0902584.
|
| ［37］ |
Zeng Y， Tao Y， Du G，et al. Advances in the mechanisms of HIF-1alpha-enhanced tumor glycolysis and its relation to dedifferentiation［J］. Prog Biophys Mol Biol， 2025， 197：1-10. DOI： 10.1016/j.pbiomolbio.2025.05.003.
|
| ［38］ |
Sharma BR， Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases［J］. Nat Immunol， 2021， 22（5）：550-559. DOI： 10.1038/s41590-021-00886-5.
|
| ［39］ |
VanPortfliet JJ， Chute C， Lei Y，et al. Mitochondrial DNA release and sensing in innate immune responses［J］. Hum Mol Genet， 2024， 33（R1）：R80-R91. DOI： 10. 1093/hmg/ddae031.
|
| ［40］ |
Yan C， Liu X， Xu H，et al. Cytoplasmic mtDNA clearance suppresses inflammatory immune responses［J］. Trends Cell Biol， 2024， 34（11）：897-900. DOI： 10.1016/j.tcb.2024.09.002.
|
| ［41］ |
Wang A， Zheng WS， Luo Z，et al. The innovative checkpoint inhibitors of lung adenocarcinoma，cg09897064 methylation and ZBP1 expression reduction，have implications for macrophage polarization and tumor growth in lung cancer［J］. J Transl Med， 2024， 22（1）：173. DOI： 10.1186/s12967-024-04995-1.
|
| ［42］ |
Zaretsky JM， Garcia-Diaz A， Shin DS，et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma［J］. N Engl J Med， 2016， 375（9）：819-829. DOI： 10.1056/NEJMoa1604958.
|
| ［43］ |
Haq R， Yokoyama S， Hawryluk EB，et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition［J］. Proc Natl Acad Sci U S A， 2013， 110（11）：4321-4326. DOI： 10.1073/pnas.1205575110.
|
| ［44］ |
Liang R， Yung MMH， He F，et al. The stress-inducible BCL2A1 is required for ovarian cancer metastatic progression in the peritoneal microenvironment［J］. Cancers （Basel）， 2021， 13（18）：4577. DOI： 10.3390/cancers13184577.
|
| ［45］ |
Vogler M， Braun Y， Smith VM，et al. The BCL2 family：from apoptosis mechanisms to new advances in targeted therapy［J］. Signal Transduct Target Ther， 2025， 10（1）：91. DOI： 10.1038/s41392-025-02176-0.
|
| ［46］ |
El-Mesery M， Rudolf F， Heimann Y，et al. Non-canonical functions of BCL-2 family members in energy metabolism and necrotic cell death regulation［J］. Cell Cycle， 2024， 23（21-24）：931-948. DOI： 10.1080/15384101.2025.2484868.
|
| ［47］ |
Ku B. Structural analysis of the interaction between Bcl-xL and the noncanonical BH3 domain of non-Bcl-2 family proteins［J］. Curr Protein Pept Sci， 2023， 24（4）：296-306. DOI： 10.2174/1389203724666230314164040.
|
| ［48］ |
Bruey JM， Bruey-Sedano N， Luciano F，et al. Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1［J］. Cell， 2007， 129（1）：45-56. DOI： 10.1016/j.cell.2007.01.045.
|
| ［49］ |
Speir M， Tye H， Gottschalk TA，et al. A1 is induced by pathogen ligands to limit myeloid cell death and NLRP3 inflammasome activation［J］. EMBO Rep， 2023， 24（11）：e56865. DOI： 10.15252/embr.202356865.
|
| ［50］ |
Xu W， Huang Y， Zhou R. NLRP3 inflammasome in neuroinflammation and central nervous system diseases［J］. Cell Mol Immunol， 2025， 22：341-355. DOI： 10.1038/s41423-025-01275-w.
|